Navigation Links
Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
Date:3/4/2013

LA JOLLA, Calif., March 4, 2013Sanford-Burnham Medical Research Institute (Sanford-Burnham) and 60 Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics. 60 Pharmaceuticals, a philanthropic-for-profit company focused on neglected and rare diseases, agreed to provide funding to Sanford-Burnham for the first phase of research to explore inhibitors of furin.

Since viral genomes are too small to encode every protein needed for their survival, they take advantage of proteins in their human hosts. For the dengue virus and numerous other virusessuch as West Nile, Ebola, or yellow feverfurin is a vital host protein. For this reason, these viruses can only attack human cells that produce furin. Scientists at Sanford-Burnham are now trying to find a way to inhibit furin, making it impossible for the dengue virus to exploit and "hijack" a host cell.

"We're working on a new small-molecule furin inhibitor. It's a challenge to design, but could solve the toxicity problem that plagues existing viral inhibitors," explains Alex Strongin, Ph.D., professor in Sanford-Burnham's Infectious and Inflammatory Disease Center.

During the first phase of the research partnership, Drs. Alex Strongin and Maurizio Pellecchia and their laboratories at Sanford-Burnham will identify the most promising lead candidate from multiple small-molecule compounds they have already synthesized and tested in cell-based tests. They will evaluate each compound's absorption and distribution in the body (pharmacokinetics), as well as toxicity and efficacy in animal models. These data will inform potential second-phase research, which will focus on further developing the lead compound for oral application.

"The partnership with Sanford-Burnham exemplifies our commitment to developing treatments for the world's most challenging and neglected diseases, such as dengue fever," adds Geoffrey Dow, CEO of 60 Pharmaceuticals. "Only a combined effort can help address these challenges and make a real difference in the lives of millions of people living in regions affected by the dengue virus. Our goal is to find a treatment that is affordable, safe in warm and humid climates, and easy to administer."

Successfully designing a small-molecule inhibitor of furin that is safe and effective could have implications far beyond dengue fever. Given the protein's prevalence and important role in the lifecycle of a variety of viruses, a potent inhibitor could eventually lead to treatment options for many more viral diseases, affecting hundreds of millions of people worldwide.


'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Californias stem cell agency boosts heart disease research at Sanford-Burnham
2. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
3. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
9. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
10. Researchers pursue red flag for schizophrenia relapse
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/19/2016)... Nov. 18, 2016 Securus Technologies, a leading ... public safety, investigation, corrections and monitoring, announced today that ... ICSolutions, to have an independent technology judge determine who ... modern high tech/sophisticated telephone calling platform, and the best ... they do most of what we do – which ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq ... applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the ... (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a truly broadband ...
(Date:11/30/2016)... Carolina (PRWEB) , ... November 30, 2016 , ... On ... names and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and ... period of public review, the names earlier proposed by the discoverers have been approved ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
(Date:11/30/2016)... -- Teil einer Investition von 5 Millionen ... ... Aptuit LLC hat heute bekannt gegeben, ... neuartige Substanzen haben die Prüfsammlung auf über 400.000 erhöht. ... Entdeckungsfähigkeiten des Unternehmens zu erweitern. Die Ausweitung, die durch ...
Breaking Biology Technology: